Single dose of the vaccine can increase vaccine coverage rapidly which is an imperative in many countries where level of vaccine uptake is not optimal.
WHO...
Sotrovimab, a monoclonal antibody already approved for mild to moderate COVID-19 in several countries gets approval by MHRA in the UK. This antibody was intelligently designed...
Three adenoviruses used as vectors to produce COVID-19 vaccines, bind to platelet factor 4 (PF4), a protein implicated in the pathogenesis of clotting disorders.
Adenovirus...
In order to raise levels of protection across the population against the Omicron variant, the Joint Committee on Vaccination and Immunisation (JCVI)1 of UK has...
The technology used by Cuba to develop protein-based vaccines against COVID-19 can lead to development of vaccines against new mutated strains in a relatively...
The B.1.1.529 variant was first reported to WHO from South Africa on 24th November 2021. The first known confirmed B.1.1.529 infection was from a specimen...
WHO’s Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) was convened on 26th November 2021 to assess the variant B.1.1.529. Based on the available evidences,...